Literature DB >> 24696021

Interleukin-28B polymorphisms and response of chronic hepatitis C patients from Indonesia to pegylated interferon/ribavirin treatment.

Bogi P Wibowo1, I D N Wibawa2, Takako Utsumi3, Syifa Mustika1, Mochamad Amin4, Rury M Wahyuni4, Hendra Kurniawan5, Agus Hendrayana6, Poernomo B Setiawan7, Laura N Yamani8, Yoshihiko Yano8, Hak Hotta8, Yoshitake Hayashi8, Maria I Lusida9.   

Abstract

This study demonstrated that Indonesian patients with chronic hepatitis C (mostly ethnic Java people) mostly were infected with hepatitis C virus (HCV) genotype 1; however, they carried mainly the major genotypes of interleukin 28B (IL-28B) single nucleotide polymorphisms (SNPs) (rs12979860 CC, rs11881222 TT, rs8103142 AA, and rs8099917 TT), and they mostly achieved sustained virological responses to pegylated interferon/ribavirin treatment.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24696021      PMCID： PMC4042733          DOI： 10.1128/JCM.00768-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  15 in total

1.  Development of new IL28B genotyping method using Invader Plus assay.

Authors:  Satomi Kani; Yasuhito Tanaka; Kentaro Matsuura; Tsunamasa Watanabe; Hiroshi Yatsuhashi; Etsuro Orito; Ken Inose; Nao Motojuku; Yukio Wakimoto; Masashi Mizokami
Journal:  Microbiol Immunol       Date:  2012-05       Impact factor: 1.955

2.  The use of real-time PCR to detect hepatitis C virus RNA in dried blood spots from Brazilian patients infected chronically.

Authors:  Carlos Santos; Alexanda Reis; Cintia Vilhena Dos Santos; Cristine Damas; Mariliza Henrique Silva; Mônica Valverde Viana; Maria Lucia Ferraz; Dimas Carnauba; Fabiane El-Far; Fernando Serra; Ricardo Sobhie Diaz
Journal:  J Virol Methods       Date:  2011-06-24       Impact factor: 2.014

3.  Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.

Authors:  Chung-Feng Huang; Jee-Fu Huang; Jeng-Fu Yang; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Cherng Chen; Liang-Yen Wang; Suh-Hang Hank Juo; Ku-Chung Chen; Wan-Long Chuang; Hsing-Tao Kuo; Chia-Yen Dai; Ming-Lung Yu
Journal:  J Hepatol       Date:  2011-05-19       Impact factor: 25.083

Review 4.  Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.

Authors:  Peter Simmonds; Jens Bukh; Christophe Combet; Gilbert Deléage; Nobuyuki Enomoto; Stephen Feinstone; Phillippe Halfon; Geneviève Inchauspé; Carla Kuiken; Geert Maertens; Masashi Mizokami; Donald G Murphy; Hiroaki Okamoto; Jean-Michel Pawlotsky; François Penin; Erwin Sablon; Tadasu Shin-I; Lieven J Stuyver; Heinz-Jürgen Thiel; Sergei Viazov; Amy J Weiner; Anders Widell
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

5.  IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection.

Authors:  Stevan A Gonzalez; Emmet B Keeffe
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-06

6.  Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.

Authors:  Andri Rauch; Zoltán Kutalik; Patrick Descombes; Tao Cai; Julia Di Iulio; Tobias Mueller; Murielle Bochud; Manuel Battegay; Enos Bernasconi; Jan Borovicka; Sara Colombo; Andreas Cerny; Jean-François Dufour; Hansjakob Furrer; Huldrych F Günthard; Markus Heim; Bernard Hirschel; Raffaele Malinverni; Darius Moradpour; Beat Müllhaupt; Andrea Witteck; Jacques S Beckmann; Thomas Berg; Sven Bergmann; Francesco Negro; Amalio Telenti; Pierre-Yves Bochud
Journal:  Gastroenterology       Date:  2010-01-11       Impact factor: 22.682

7.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

8.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

9.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

Review 10.  Expert opinion on the treatment of patients with chronic hepatitis C.

Authors:  S Zeuzem; T Berg; B Moeller; H Hinrichsen; S Mauss; H Wedemeyer; C Sarrazin; D Hueppe; E Zehnter; M P Manns
Journal:  J Viral Hepat       Date:  2008-08-28       Impact factor: 3.728
View more
  1 in total

Review 1.  APASL consensus statements and recommendation on treatment of hepatitis C.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-04-29       Impact factor: 6.047
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.